Azimzade Y, Haugen MH, Kristensen VN, Frigessi A, Köhn-Luque A(2026) Explainable machine learning-guided integrated multiomics analysis reveals macrophage-driven immune suppression in breast cancer Nat Commun(in press) DOI 10.1038/s41467-026-73617-9, PubMed 42185288
Parissenti AM, Pritzker LB, Dahle MA, Gythfeldt HVL, Masilamani T, Theriault G, St-Onge R, D'costa L, Lingjaerde OC, Haugen MH, Engebraaten O(2025) High mid-treatment tumour RNA disruption in patients with HER2-negative breast cancer is associated with improved disease-free survival after neoadjuvant chemotherapy Breast Cancer Res, 27(1), 143 DOI 10.1186/s13058-025-02092-9, PubMed 40790765
Egeland EV, Seip K, Skourti E, Øy GF, Pettersen SJ, Pandya AD, Dahle MA, Haugen MH, Kristian A, Nakken S, Engebraaten O, Mælandsmo GM, Prasmickaite L(2024) The SRC-family serves as a therapeutic target in triple negative breast cancer with acquired resistance to chemotherapy Br J Cancer, 131(10), 1656-1667 DOI 10.1038/s41416-024-02875-5, PubMed 39390250
